Compare Stocks: TLSA, ATOS, ETON, and FSDC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.07 -5.5%	$2.90	$1.70 ▼ $19.35	$18.86M	1.25	101,307 shs	79,039 shs
ETON Eton Pharmaceuticals	$46.42 -5.3%	$35.98	$13.78 ▼ $50.18	$1.34B	0.86	516,413 shs	484,784 shs
FSDC FS Development	$66.85 +1.6%	$13.90	$9.80 ▼ $13.75	$836.70M	N/A	332,704 shs	415,625 shs
TLSA Tiziana Life Sciences	$1.03 +6.2%	$1.18	$0.87 ▼ $2.60	$123.44M	0.46	251,011 shs	388,461 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-5.19%	-9.13%	+13.47%	-59.22%	-83.26%
ETON Eton Pharmaceuticals	+1.87%	+11.08%	+35.44%	+103.28%	+237.67%
FSDC FS Development	0.00%	0.00%	0.00%	0.00%	+11.79%
TLSA Tiziana Life Sciences	+1.17%	-4.90%	-24.22%	-24.22%	-59.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.07 -5.5%	$2.90	$1.70 ▼ $19.35	$18.86M	1.25	101,307 shs	79,039 shs
ETON Eton Pharmaceuticals	$46.42 -5.3%	$35.98	$13.78 ▼ $50.18	$1.34B	0.86	516,413 shs	484,784 shs
FSDC FS Development	$66.85 +1.6%	$13.90	$9.80 ▼ $13.75	$836.70M	N/A	332,704 shs	415,625 shs
TLSA Tiziana Life Sciences	$1.03 +6.2%	$1.18	$0.87 ▼ $2.60	$123.44M	0.46	251,011 shs	388,461 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-5.19%	-9.13%	+13.47%	-59.22%	-83.26%
ETON Eton Pharmaceuticals	+1.87%	+11.08%	+35.44%	+103.28%	+237.67%
FSDC FS Development	0.00%	0.00%	0.00%	0.00%	+11.79%
TLSA Tiziana Life Sciences	+1.17%	-4.90%	-24.22%	-24.22%	-59.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.20	Hold	$20.33	882.29% Upside
ETON Eton Pharmaceuticals	2.50	Moderate Buy	$52.50	13.10% Upside
FSDC FS Development	0.00	N/A	N/A	N/A
TLSA Tiziana Life Sciences	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $62.00
7/17/2026	ETON Eton Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00
7/16/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2026	TLSA Tiziana Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/13/2026	ETON Eton Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/11/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/29/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/22/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/15/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $57.00

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ETON Eton Pharmaceuticals	$79.95M	15.90	$0.00 per share	9,459.41	$0.98 per share	47.37
FSDC FS Development	N/A	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.21	N/A	N/A	N/A	N/A	-84.91%	-72.36%	8/11/2026 (Estimated)
ETON Eton Pharmaceuticals	-$4.60M	-$0.07	N/A	24.30	N/A	-1.70%	-5.68%	-1.49%	8/6/2026 (Estimated)
FSDC FS Development	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/18/2026 (Estimated)

Latest TLSA, ATOS, ETON, and FSDC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ATOS Atossa Genetics	-$1.04	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.13	N/A	N/A	N/A	$27.11 million	N/A
5/14/2026	Q1 2026	ETON Eton Pharmaceuticals	$0.10	$0.05	-$0.05	$0.05	$22.31 million	$24.27 million
5/8/2026	Q1 2026	ATOS Atossa Genetics	-$0.99	-$1.11	-$0.12	-$1.11	N/A	N/A
5/1/2026	Q4 2025	TLSA Tiziana Life Sciences	N/A	-$0.2750	N/A	-$0.2750	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FSDC FS Development	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	4.92	4.92
ETON Eton Pharmaceuticals	0.62	1.21	0.88
FSDC FS Development	N/A	2.91	2.91
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ETON Eton Pharmaceuticals	27.86%
FSDC FS Development	89.82%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ETON Eton Pharmaceuticals	16.49%
FSDC FS Development	N/A
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	8.61 million	7.77 million	Optionable
ETON Eton Pharmaceuticals	20	27.39 million	22.88 million	Optionable
FSDC FS Development	N/A	12.52 million	N/A	Not Optionable
TLSA Tiziana Life Sciences	8	127.26 million	76.58 million	Optionable

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31 at 1:32 PM | benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

July 31 at 8:56 AM | proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31 at 8:29 AM | finance.yahoo.com

CNS Pharmaceuticals (NASDAQ:CNSP) and Tiziana Life Sciences (NASDAQ:TLSA) Head-To-Head Review

July 26, 2026 | americanbankingnews.com

Tiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks Research

July 16, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 8.1% - What's Next?

July 13, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest Report

July 13, 2026 | benzinga.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

June 25, 2026 | proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026 | globenewswire.com

Why Tiziana Life Sciences Is Back on the Small-Cap Radar?

June 19, 2026 | kalkinemedia.comK

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026 | globenewswire.com

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 29, 2026 | finanznachrichten.de

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026 | globenewswire.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data â€“ ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

May 21, 2026 | finance.yahoo.com

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

May 21, 2026 | proactiveinvestors.com

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

May 21, 2026 | globenewswire.com

Tiziana Life Sciences price target boosted on foralumab update

May 19, 2026 | proactiveinvestors.com

Tiziana says updated data for multiple sclerosis therapy shows long-term safety

May 19, 2026 | seekingalpha.com

Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS

May 19, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.07 -0.12 (-5.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 0.00 (0.00%)

As of 07:41 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Eton Pharmaceuticals NASDAQ:ETON

$46.42 -2.61 (-5.32%)

Closing price 04:00 PM Eastern

Extended Trading

$46.38 -0.04 (-0.08%)

As of 07:34 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

FS Development NASDAQ:FSDC

FS Development Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was founded in 2020 and is based in San Francisco, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.03 +0.06 (+6.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 -0.01 (-0.49%)

As of 07:34 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, ATOS, ETON, and FSDC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

Eton Pharmaceuticals NASDAQ:ETON

FS Development NASDAQ:FSDC

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, ATOS, ETON, and FSDC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, ATOS, ETON, and FSDC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, ATOS, ETON, and FSDC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TLSA, ATOS, ETON, and FSDC Company Descriptions

Atossa Genetics NASDAQ:ATOS

Eton Pharmaceuticals NASDAQ:ETON

FS Development NASDAQ:FSDC

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools